eligibility_summary
Adults ≥18, consent. Phase 1a: refractory advanced solid tumors (GBM/CNS allowed on ≤2 mg/d dex). Phase 1b: non‑sq NSCLC post anti‑PD‑(1/L1), ≤2 lines, no driver mutations, or immunotherapy‑naïve MSS‑CRC after ≥2 lines. SOC: doxo‑eligible STS (excl Ewing/GIST/Kaposi) or tebentafusp‑eligible uveal melanoma. Measurable, biopsy‑amenable, ECOG 0–2 (0–1 exp), adequate organs, controlled HIV, contraception. Exclude therapy/radiation/surgery, infection, active CNS mets, thrombosis, HBV/HCV, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests: DCSZ11 (anti-CD93 monoclonal antibody, IV) as monotherapy, DCSZ11 + pembrolizumab (anti–PD‑1 IgG4), and DCSZ11 + standard of care: doxorubicin (anthracycline DNA intercalator/topoisomerase II inhibitor) in soft-tissue sarcoma, and tebentafusp (bispecific TCR/CD3 ImmTAC targeting gp100/HLA‑A02:01 and CD3) in uveal melanoma. Targets/mechanisms: DCSZ11 binds CD93 on tumor endothelium and myeloid cells to modulate tumor vasculature/angiogenesis and the immunosuppressive microenvironment, pembrolizumab blocks PD‑1 on T cells to restore antitumor immunity, doxorubicin damages DNA in proliferating tumor cells via intercalation, topo II inhibition, and ROS, tebentafusp redirects T cells to gp100+ melanoma cells via CD3 engagement.